Idxg stock.

Dr D IDXG stock SEC Form 4 insiders trading. Dr has made over 1 trades of the Interpace Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,855 units of IDXG stock worth $94,221 on 21 May 2021.10,855 units of IDXG stock worth $94,221 on 21 May 2021.Find the latest Research Frontiers Incorporated (REFR) stock quote, history, news and other vital information to help you with your stock trading and investing.Parsippany, NJ, March 11, 2020 (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross Blue Shield of Massachusetts.While terms of this Agreement are not disclosed, Interpace is an in-network lab with Blue Cross Blue Shield of …Interpace Biosciences Inc. advanced stock charts by MarketWatch. View IDXG historial stock data and compare to other stocks and exchanges. Interpace Biosciences (IDXG) Stock Price Performance. Interpace Biosciences (IDXG) Stock Key Data ... Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months.

Interpace Biosciences Inc. historical stock charts and prices, analyst ratings, financials, and today’s real-time IDXG stock price. MiMedx Group (MDXG, $7.57) RSI Indicator left the overbought zone on November 22, 2023. Track Mimedx Group Inc (MDXG) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors.

Find the latest Interpace Biosciences, Inc. (IDXG) stock quote, history, news and other vital information to help you with your stock trading and investing.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for IDXG as an investment opportunity. To contextualize these metrics, consider that out of all US stocks, INTERPACE BIOSCIENCES INC's number of analysts covering the stock is higher than practically ...Interpace Diagnostics Announces Launch of Enhancement to Thyroid Testing Services New Molecular Marker of Aggressiveness Being Added to ThyGenX Test Offering PRStock Price Forecast. The 1 analysts offering 12-month price forecasts for Interpace Biosciences Inc have a median target of 11.00, with a high estimate of 11.00 and a low estimate of 11.00. The median estimate represents a +909.17% increase from the last price of 1.09. Chart unavailable. Current. N/A. 1 Month Ago. N/A. 3 Months Ago. N/A. Interpace Biosciences Inc. analyst estimates, including IDXG earnings per share estimates and analyst recommendations.

© Valve Corporation สงวนสิทธิ์ทุกประการ เครื่องหมายการค้าทั้งหมดเป็น ...

Company Info Interpace Biosciences Inc. Waterview Plaza. Suite 310. 2001 Route 46. Parsippany New Jersey 07054. United States. Website. Map. Employees 94.

Stock Symbol NASDAQ:IDXG. Funding Rounds 1. Total Funding Amount $3.9M. Total Funding Amount . Unlock for free . Funding. Interpace Biosciences has raised a total of . $3.9M. in funding over 1 round. This was a Post-IPO Equity round raised on Feb 8, 2017. Interpace Biosciences is registered under the ticker NASDAQ:IDXG .Find the latest iBX Group, Inc. (IBXG) stock quote, history, news and other vital information to help you with your stock trading and investing. Find the latest Accelerate Diagnostics, Inc. (AXDX) stock quote, history, news and other vital information to help you with your stock trading and investing.On Wednesday, October 14, 2020, the Company, Interpace Biosciences, Inc., IDXG stock construct a change of 32.89 percent (↑ /When it comes to purchasing a new vehicle, finding the perfect car that meets all your requirements can be a daunting task. If you have your heart set on a Genesis GV70, you’ll want to ensure that you find the best one available in stock.Aug 17, 2020 · Interpace Biosciences Inc (IDXG) stock is down -31.64% while the S&P 500 is up 0.35% as of 2:31 PM on Monday, Aug 17. IDXG is down -$1.83 from the previous closing price of $5.78 on volume of 968,030 shares. Over the past year the S&P 500 has risen 15.77% while IDXG is down -47.33%. IDXG lost -$8.53 per share the over the last 12 months. © Valve Corporation. All rights reserved. All trademarks are property of their respective owners in the US and other countries. #footer_privacy_policy | #footer ...

Dr D IDXG stock SEC Form 4 insiders trading. Dr has made over 1 trades of the Interpace Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,855 units of IDXG stock worth $94,221 on 21 May 2021.10,855 units of IDXG stock worth $94,221 on 21 May 2021.Overview Profile Financials Income Statement Balance Sheet Cash Flow Research & Ratings Historical Prices Options Advanced Charting News Interpace Biosciences Inc. …IDXG Stock Return DVA Stock Return ... We favor stocks that offer meaningfully greater expected return in the next 3 years; These returns are calculated based on our revenue forecast and Price to Sales Ratio (P/S) scenarios considered; Similar Price To Sales Ratio (P/S) scenarios are considered for both stocks and each scenario is weighted ...Jun 5, 2023 · 06/05/2023 - 04:05 PM . PARSIPPANY, NJ, June 05, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the Centers for Medicare & Medicaid Services (CMS) issued the final Local Coverage Determination (LCD) of Genetic Testing for Oncology (L39365) which establishes non-coverage for the Company’s widely used PancraGEN ... IDXG Stock Return DVA Stock Return ... We favor stocks that offer meaningfully greater expected return in the next 3 years; These returns are calculated based on our revenue forecast and Price to Sales Ratio (P/S) scenarios considered; Similar Price To Sales Ratio (P/S) scenarios are considered for both stocks and each scenario is weighted ...

When picking the best stocks under $10 to buy, it's important to identify fundamentally strong and non-speculative stocks. These are fundamentally strong and non-speculative stocks that are under $10 Since the meme stock euphoria in 2020, i...

Interpace Biosciences press release (OTCQX:IDXG): Q1 GAAP EPS of $0.10.Revenue of $9.8M (-5.6% Y/Y). ... @Lydie Agreed, surprised the stock did not pop more on news of sale of the pharma business ...On Wednesday, October 14, 2020, the Company, Interpace Biosciences, Inc., IDXG stock construct a change of 32.89 percent (↑ /PARSIPPANY NJ, June 20, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that its ThyGeNEXT™ and ThyraMIR ® tests for thyroid cancer are now covered by Independence Blue Cross (Independence), providing plan benefits coverage for its members who meet established medical criteria for the …Before I purchase a stock, it must meet stringent criteria within my investment strategy or I do not buy. Walletinvestor is a critical part of my strategy. It also makes it easy to find stocks to invest in by sorting with filters like projected returns, price of stock, rating of stock, etc. Date of experience: June 22, 20216201 15th Avenue. Brooklyn, NY 11219. T: 718-921-8300. [email protected]. www.astfinancial.com. Interpace Biosciences® is a dynamic and growing leader in the life sciences industry, providing complex molecular analysis for the early diagnosis and treatment of cancer. Interpace Biosciences is a fully integrated commercial and ... Interpace Biosciences Inc. Annual stock financials by MarketWatch. View the latest IDXG financial statements, income statements and financial ratios.Oct 16, 2023 · Interpace Biosciences GAAP EPS of -$0.53, revenue of $10.38M. SA NewsMon, May 16, 2022 1 Comment.

View the latest Interpace Biosciences Inc. (IDXG) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Joseph D Keegan - IDXG / Interpace Diagnostics Group, Inc. - Insider Trade Report ... (Stocks) Options Flow - Last 7 Days (ETF) Gamma Squeeze; Gamma Pockets; Put/Call Ratio - Top Bullish; Put Call Ratio - Top Bearish; SEC FILINGS SEC Forms Latest S1 (IPO) Filings Latest 13D/G Filings Latest 13F Filings. SCREENER

Dr D IDXG stock SEC Form 4 insiders trading. Dr has made over 1 trades of the Interpace Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,855 units of IDXG stock worth $94,221 on 21 May 2021.10,855 units of IDXG stock worth $94,221 on 21 May 2021.Interpace Biosciences Stock Price, News & Analysis (NASDAQ:IDXG) Notice: This company has been marked as potentially delisted and may not be actively …© Valve Corporation. Tutti i diritti riservati. Tutti i marchi appartengono ai rispettivi proprietari negli Stati Uniti e in altri Paesi. #footer_privacy_policy | # ...Stock Symbol NASDAQ:IDXG. Funding Rounds 1. Total Funding Amount $3.9M. Total Funding Amount . Unlock for free . Funding. Interpace Biosciences has raised a total of . $3.9M. in funding over 1 round. This was a Post-IPO Equity round raised on Feb 8, 2017. Interpace Biosciences is registered under the ticker NASDAQ:IDXG .IDXG Overview Stock Screener Earnings Calendar Sectors | IDXG U.S.: OTC Interpace Biosciences Inc. Watch list NEW Set a price target alert Closed Last Updated: Nov 1, 2023 3:48 p.m. EDT... View Interpace Biosciences, Inc IDXG investment & stock information. Get the latest Interpace Biosciences, Inc IDXG detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Interpace Biosciences Inc. advanced stock charts by MarketWatch. View IDXG historial stock data and compare to other stocks and exchanges.Parsippany, NJ, May 17, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that it will offer a new capability in providing Digital Spatial Profiling services using the novel GeoMx ® testing platform. GeoMx ® combines the benefits of …

What is the ownership structure of IDXG? Owner Type Number of Shares Ownership Percentage; Institutions: 143,857: 3.3%: Individual Insiders: 1,100,552: 25.5%Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.Stock Split Watch: 2 Monster Growth Stocks Up 376% and 1,160% in 5 Years to Buy Before 2024 2 Key Things From Nvidia's Earnings Call That Investors Should Know 1 Green Flag for Nvidia in 2023, and ...Interpace Biosciences, Inc. (NASDAQ:IDXG) released its earnings results on Wednesday, November, 8th. The business services provider reported ($0.12) EPS for the quarter. The business services provider had revenue of $9.08 million for the quarter.Instagram:https://instagram. how much is workers comp insurance for self employedpre market volumeaves etfww stocks Interpace Diagnostics Announces European Patent Approval For Underlying Technology of its ThyraMIR® microRNA Classifier PR Newswire PARSIPPANY, N.J., April 3, texas temporary health insurancekvue stock dividend Interpace Biosciences, Inc. company earnings calendar and analyst expectations - Upcoming and past events | OTC Markets: IDXG | OTC MarketsInterpace Biosciences Inc stock is down 4.75% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator. Interpace Biosciences Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on IDXG! large investment firms Jul 1, 2021 · Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results. Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective December 31, 2020.He will be replaced as President and Chief Executive Officer by Thomas Burnell, PhD., effective December 1, 2020.60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share.